

ABSTRACT OF THE DISCLOSURE

A method of determining a potential of a diabetic patient to benefit anti oxidant therapy for treatment of a vascular complication, the method comprises determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit said anti oxidant therapy, whereby a patient having a haptoglobin 2/2 phenotype benefits anti oxidant therapy more than a patient having a haptoglobin 1/2 phenotype or a patient having a haptoglobin 1/1 phenotype.